Glioblastoma is an unmet clinical need. Local treatment strategies offer advantages, such as
the possibility to bypass the blood–brain barrier, achieving high drug concentrations at the …

The efficacy of standard glioblastoma (GBM) treatments has been limited due to the highly
immunosuppressive tumor immune microenvironment, interpatient tumor heterogenicity and …

Gliomas are the most common and lethal type of primary malignant brain tumor. But the
existence of blood brain barrier (BBB) and blood-tumor barrier (BTB) hinder drug from …

Effective chemotherapy delivery for glioblastoma multiforme (GBM) is limited by drug
transport across the blood–brain barrier and poor efficacy of single agents. Polymer–drug …

In recent years, hyaluronic acid (HA) has attracted significant interest in development of drug
delivery systems because of its intrinsic physicochemical and biological properties …

Hyaluronic acid (HA) is a naturally-occurring glycosaminoglycan and a major component of
the extracellular matrix. Low levels of the hyaluronic acid receptor CD44 are found on the …

Over the last few years, significant interest has emerged in the development of localised
therapeutic strategies for the treatment of glioblastoma (GBM). The concept of attracting and …

Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …

Purpose. Overexpression of hyaluronan (HA) receptors on cancer cells results in enhanced
endocytotic uptake of the drug conjugate. An N-(2-hydroxypropyl) methacrylamide (HPMA) …

Glioblastoma Multiforme (GBM) is a highly prevalent and deadly brain malignancy
characterized by poor prognosis and restricted disease management potential. Despite the …